Akebia Therapeutics Q2 revenue smashes expectations
Overview
Akebia Q2 2025 revenue rises to $62.5 mln, beating analyst expectations
Net income for Q2 2025 beats estimates, reaching $0.2 mln
Company expands Vafseo prescribing access through dialysis partnerships
Result Drivers
VAFSEO GROWTH - Prescription demand for Vafseo increased by 55% over Q1 2025, with more than 725 prescribers writing prescriptions
DIALYSIS PARTNERSHIPS - Akebia is expanding Vafseo access through partnerships with DaVita, DCI, and IRC, expecting protocols to reach over 75,000 patients by end of Q3
REFILL PRESCRIPTIONS - Over 80% of Vafseo prescriptions in Q2 were refills, with average dose increasing by 25%
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $62.47 mln | $47.20 mln (5 Analysts) |
Q2 EPS |
|
| -$0.02 (4 Analysts) |
Q2 Net Income | Beat | $247,000 | -$4.67 mln (4 Analysts) |
Q2 Operating Income | Beat | $14.09 mln | $2.03 mln (3 Analysts) |
Q2 Basic EPS |
|
|
|
Q2 Operating Expenses |
| $38.46 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 45.9% above its August 6 closing price of $3.79
Press Release: ID:nGNX86RVjh
